| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | NEUTRAL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.18▼ | 8.20▼ | 8.21▼ | 8.41▼ | 8.13▲ |
| MA10 | 8.19▼ | 8.21▼ | 8.29▼ | 8.39▼ | 8.03▲ |
| MA20 | 8.19▼ | 8.30▼ | 8.38▼ | 8.15▲ | 8.12▲ |
| MA50 | 8.22▼ | 8.40▼ | 8.36▼ | 8.06▲ | 8.62▼ |
| MA100 | 8.28▼ | 8.35▼ | 8.35▼ | 8.05▲ | 9.74▼ |
| MA200 | 8.37▼ | 8.32▼ | 7.95▲ | 8.25▼ | 7.10▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.005▼ | -0.031▼ | 0.012▲ | 0.082▲ |
| RSI | 43.095▼ | 39.669▼ | 38.387▼ | 50.477▲ | 50.067▲ |
| STOCH | 42.863 | 39.288 | 18.027▼ | 54.169 | 47.741 |
| WILL %R | -61.538 | -84.337▼ | -86.735▼ | -82.482▼ | -45.595 |
| CCI | -53.529 | -40.736 | -74.130 | -109.932▼ | 3.285 |
|
Monday, September 07, 2026 05:00 PM
On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 ...
|
|
Thursday, August 13, 2026 05:00 PM
CorMedix 2026年第二季度每股收益为$0.29，超出预期$0.06；营收达$1.019亿，超出预测$630万，推动股价上涨15.77%至$8.22。
|
|
Wednesday, July 29, 2026 01:30 AM
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 08/09/26 | 8.28 | 8.37 | 8.11 | 8.18 | 1,099,087 |
| 04/09/26 | 8.45 | 8.605 | 8.31 | 8.43 | 792,812 |
| 03/09/26 | 8.69 | 8.745 | 8.43 | 8.47 | 706,670 |
| 02/09/26 | 8.40 | 8.62 | 8.33 | 8.61 | 1,101,682 |
| 01/09/26 | 8.25 | 8.4801 | 8.18 | 8.38 | 880,231 |
| 31/08/26 | 8.26 | 8.29 | 8.06 | 8.26 | 980,527 |
| 28/08/26 | 8.28 | 8.395 | 8.185 | 8.30 | 775,762 |
| 27/08/26 | 8.45 | 8.49 | 8.2803 | 8.31 | 700,984 |
| 26/08/26 | 8.60 | 8.605 | 8.37 | 8.39 | 865,057 |
| 25/08/26 | 8.35 | 8.575 | 8.28 | 8.56 | 1,232,094 |
|
|
||||
|
|
||||
|
|